Almirall seeks partnership
This article was originally published in Scrip
Executive Summary
The Spanish pharmaceutical company Almirall is aiming to strike a deal for the development and commercialisation of its long-acting beta agonist, LAS100977. The new, unnamed chemical entity could be a step forward in the treatment of asthma and chronic obstructive pulmonary disease, the company says.